{"id":436128,"date":"2026-06-02T07:25:59","date_gmt":"2026-06-02T07:25:59","guid":{"rendered":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/?p=436128"},"modified":"2026-07-13T07:30:51","modified_gmt":"2026-07-13T07:30:51","slug":"the-hidden-complexity-of-pharmaceutical-competitive-intelligence-data","status":"publish","type":"post","link":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/blog\/the-hidden-complexity-of-pharmaceutical-competitive-intelligence-data\/","title":{"rendered":"\u4e00\u79cd\u836f\u7269\uff0c\u4e03\u4e2a\u540d\u79f0\uff1a\u836f\u7269\u7ade\u4e89\u60c5\u62a5\u6570\u636e\u80cc\u540e\u9690\u85cf\u7684\u590d\u6742\u6027"},"content":{"rendered":"<p>2018 \u5e74 3 \u6708\uff0cCelgene \u4ee5 90 \u4ebf\u7f8e\u5143\u5b8c\u6210\u5bf9 Juno Therapeutics \u7684\u6536\u8d2d\uff0c\u4ece\u800c\u83b7\u5f97\u5f53\u65f6\u540d\u4e3a JCAR017 \u7684\u5d4c\u5408\u6297\u539f\u53d7\u4f53 T \u7ec6\u80de\uff08CAR-T\uff09\u7597\u6cd5\u9879\u76ee\u7684\u5168\u90e8\u6743\u76ca\u3002\u4e00\u5e74\u540e\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u4ee5 740 \u4ebf\u7f8e\u5143\u6536\u8d2d\u4e86 Celgene\uff0c\u8be5\u8d44\u4ea7\u4e5f\u968f\u4e4b\u6613\u4e3b\u3002\u622a\u81f3 2021 \u5e74\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e86\u8be5\u836f\u7269\uff0c\u5176\u4f7f\u7528\u7684\u540d\u79f0\u662f\u4e1a\u5185\u5927\u591a\u6570\u4eba\u5728\u5176\u5f00\u53d1\u8fc7\u7a0b\u4e2d\u4ece\u672a\u542c\u95fb\u8fc7\u7684\uff1alisocabtagene maraleucel\uff0c\u5546\u54c1\u540d\u4e3a Breyanzi\u3002<sup>1, 2, 3, 4<\/sup><\/p>\n<p>\u5982\u4eca\uff0cBreyanzi \u662f\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u4e94\u79cd\u4e0d\u540c\u764c\u75c7\u7c7b\u578b\u7684 CAR-T \u7597\u6cd5\u3002\u8fd9\u4e5f\u6070\u597d\u8bf4\u660e\u4e86\u4e3a\u4ec0\u4e48\u5efa\u7acb\u4e00\u4e2a\u53ef\u9760\u7684\u836f\u7269\u7ade\u4e89\u60c5\u62a5\u6570\u636e\u5e93\u5982\u6b64\u56f0\u96be\u2014\u2014\u4ee5\u53ca\u4e3a\u4ec0\u4e48\u7ecf\u6574\u7406\u7684\u60c5\u62a5\u4e0e\u539f\u59cb\u6570\u636e\u6c47\u603b\u4e4b\u95f4\u7684\u5dee\u5f02\uff0c\u5bf9\u4e8e\u4f9d\u8d56\u4e8e\u6b64\u7684\u6bcf\u4e00\u9879\u51b3\u7b56\u800c\u8a00\u90fd\u81f3\u5173\u91cd\u8981\u3002<sup>5<\/sup><\/p>\n<h3><strong>\u4e3a\u4ec0\u4e48\u836f\u7269\u547d\u540d\u4f1a\u4f7f\u836f\u7269\u6570\u636e\u5982\u6b64\u590d\u6742<\/strong><\/h3>\n<p>\u4e00\u79cd\u836f\u7269\u4ece\u5b66\u672f\u5b9e\u9a8c\u5ba4\u7ecf\u7531\u521d\u521b\u516c\u53f8\u3001\u6536\u8d2d\u65b9\u76f4\u81f3\u5168\u7403\u5236\u836f\u516c\u53f8\uff0c\u5b83\u5728\u6bcf\u4e2a\u9636\u6bb5\u90fd\u4f1a\u7d2f\u79ef\u4e0d\u540c\u7684\u6807\u8bc6\u7b26\u3002\u6bcf\u4e00\u4e2a\u6807\u8bc6\u7b26\u5728\u5176\u51fa\u73b0\u7684\u80cc\u666f\u4e0b\u90fd\u662f\u6b63\u786e\u7684\u3002\u6bcf\u4e00\u4e2a\u90fd\u51fa\u73b0\u5728\u4e0d\u540c\u7c7b\u578b\u7684\u4fe1\u606f\u6765\u6e90\u4e2d\u3002\u8fd9\u4e9b\u6807\u8bc6\u7b26\u4e4b\u95f4\u5e76\u4e0d\u4f1a\u81ea\u52a8\u5efa\u7acb\u5173\u8054\u3002<\/p>\n<p>\u5bf9\u4e8e lisocabtagene maraleucel\uff0c\u8fd9\u4e9b\u6807\u8bc6\u7b26\u5305\u62ec\uff1a<\/p>\n<ul>\n<li><strong>Lisocabtagene maraleucel <\/strong>&#8211; \u56fd\u9645\u975e\u4e13\u5229\u540d\u79f0\uff08INN\uff09\uff0c\u662f\u76d1\u7ba1\u7533\u62a5\u6587\u4ef6\u548c\u540c\u884c\u8bc4\u5ba1\u671f\u520a\u4e2d\u7684\u6807\u51c6\u540d\u79f0<sup>1,6<\/sup><\/li>\n<li><strong>Breyanzi <\/strong>&#8211; \u5546\u4e1a\u5ba3\u4f20\u548c\u652f\u4ed8\u65b9\u627f\u4fdd\u653f\u7b56\u4e2d\u4f7f\u7528\u7684\u5546\u54c1\u540d<sup>7<\/sup><\/li>\n<li><strong>Liso-cel <\/strong>&#8211; \u5728\u533b\u5b66\u4f1a\u8bae\u548c\u4e34\u5e8a\u6587\u732e\u4e2d\u6210\u4e3a\u6807\u51c6\u7528\u6cd5\u7684\u7b80\u79f0<sup>8<\/sup><\/li>\n<li><strong>JCAR017 <\/strong>&#8211; Juno Therapeutics \u7684\u539f\u59cb\u7814\u53d1\u4ee3\u53f7\uff0c\u51fa\u73b0\u5728\u65e9\u671f\u8bd5\u9a8c\u6ce8\u518c\u548c\u5f00\u53d1\u9636\u6bb5\u51fa\u7248\u7269\u4e2d<sup>2, 9<\/sup><\/li>\n<li><strong>BMS-986387 <\/strong>&#8211; Celgene \u6536\u8d2d\u6848\u540e\u542f\u7528\u7684\u7ba1\u7ebf\u6807\u8bc6\u7b26\uff0c\u51fa\u73b0\u4e8e\u516c\u53f8\u5185\u90e8\u53ca\u76d1\u7ba1\u7533\u62a5\u6587\u4ef6\u4e2d<\/li>\n<li><strong>\u6297 <\/strong><strong>CD19 CAR-T <\/strong><strong>\u7597\u6cd5 <\/strong>&#8211; \u65e9\u671f\u4e13\u5229\u548c\u4e34\u5e8a\u524d\u7814\u7a76\u4e2d\u4f7f\u7528\u7684\u63cf\u8ff0\u6027\u672f\u8bed<\/li>\n<li><strong>SCRI-CAR19v1 <\/strong>&#8211; \u7814\u7a76\u8005\u53d1\u8d77\u7684\u8f6c\u5316\u7814\u7a76\u4e2d\u6240\u4f7f\u7528\u7684\u6784\u5efa\u4f53\u540d\u79f0<\/li>\n<\/ul>\n<p>\u4e00\u540d\u641c\u7d22\u201cJCAR017\u201d\u7684\u751f\u7269\u5236\u836f\u5206\u6790\u5e08\u548c\u4e00\u540d\u641c\u7d22\u201cBreyanzi\u201d\u7684\u540c\u4e8b\uff0c\u4ed6\u4eec\u7814\u7a76\u7684\u662f\u540c\u4e00\u9879\u8d44\u4ea7\u3002\u5efa\u7acb\u8fd9\u79cd\u5173\u8054\u9700\u8981\u7684\u4e0d\u4ec5\u4ec5\u662f\u5173\u952e\u8bcd\u5339\u914d\uff0c\u800c\u662f\u9700\u8981\u4e00\u4e2a\u5b9e\u4f53\u89e3\u6790\u6846\u67b6\uff0c\u4e14\u8be5\u6846\u67b6\u9700\u7531\u771f\u6b63\u4e86\u89e3\u836f\u7269\u5f00\u53d1\u5982\u4f55\u8fd0\u4f5c\u7684\u4eba\u5458\u6765\u6784\u5efa\u548c\u7ef4\u62a4\u3002<\/p>\n<h3><strong>\u516c\u53f8\u540d\u79f0\u7684\u53d8\u66f4\u901f\u5ea6\u4e0d\u4e9a\u4e8e\u836f\u7269\u540d\u79f0<\/strong><\/h3>\n<p>Breyanzi \u80cc\u540e\u7684\u6240\u6709\u6743\u94fe\u9020\u6210\u4e86\u7b2c\u4e8c\u5c42\u89e3\u6790\u590d\u6742\u6027\uff0c\u56e0\u4e3a\u94fe\u4e2d\u7684\u6bcf\u5bb6\u516c\u53f8\u6839\u636e\u6587\u4ef6\u7684\u64b0\u5199\u65f6\u95f4\u548c\u5730\u70b9\u7684\u4e0d\u540c\u800c\u4ee5\u4e0d\u540c\u7684\u540d\u79f0\u51fa\u73b0\u3002<\/p>\n<p>Juno Therapeutics \u4f5c\u4e3a\u521b\u59cb\u516c\u53f8\uff0c\u5728\u4e3b\u8981\u4fe1\u606f\u6765\u6e90\u4e2d\u4ee5 Juno Therapeutics\u3001Juno Therapeutics Inc.\u3001Juno Therapeutics LLC\u548cJuno\uff08Celgene\uff09\u7b49\u5f62\u5f0f\u51fa\u73b0\uff0c\u8fd9\u4e9b\u53d8\u5316\u662f\u7531\u5176\u751f\u547d\u5468\u671f\u9636\u6bb5\u548c\u516c\u53f8\u53d8\u66f4\u6240\u81f4\u3002Celgene \u4e8e 2018 \u5e74\u521d\u5b8c\u6210\u4e86\u5bf9 Juno \u7684\u6536\u8d2d\uff0c\u5728\u4e0d\u540c\u4fe1\u606f\u6765\u6e90\u4e2d\u88ab\u7d22\u5f15\u4e3a Celgene\u3001Celgene Corporation\u3001Celgene Corp.\u3001Celgene Inc.\u3001Celgene\/BMS \u4ee5\u53ca\u80a1\u7968\u4ee3\u7801 CELG\u3002\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u5728 2019 \u5e74\u4ee5 740 \u4ebf\u7f8e\u5143\u6536\u8d2d Celgene \u540e\u7684\u5f53\u524d\u6240\u6709\u8005\uff0c\u4ee5 Bristol Myers Squibb Company\u3001Bristol-Myers Squibb \u548c BMS \u7b49\u5f62\u5f0f\u51fa\u73b0\u3002<sup>4,10, 11,12<\/sup><\/p>\n<p>\u82e5\u8981\u8ffd\u6eaf\u67d0\u9879\u836f\u7269\u662f\u7531\u8c01\u3001\u4f55\u65f6\u4ee5\u53ca\u5728\u54ea\u4e2a\u4f01\u4e1a\u5b9e\u4f53\u4e0b\u5f00\u53d1\u7684\uff0c\u5c31\u9700\u8981\u540c\u65f6\u89e3\u6790\u836f\u7269\u6807\u8bc6\u7b26\u3001\u516c\u53f8\u540d\u79f0\u548c\u6240\u6709\u6743\u53d8\u8fc1\u7684\u65f6\u95f4\u7ebf\u3002\u8fd9\u4e09\u4e2a\u5c42\u9762\u4e2d\u7684\u4efb\u4f55\u4e00\u4e2a\u51fa\u73b0\u5339\u914d\u9057\u6f0f\uff0c\u90fd\u4f1a\u5bfc\u81f4\u9879\u76ee\u5f52\u5c5e\u9519\u8bef\u3001\u7ade\u4e89\u5386\u53f2\u7f3a\u5931\u6216\u662f\u5bf9\u6536\u8d2d\u8d44\u4ea7\u4ef7\u503c\u7684\u8bef\u5224\u3002<\/p>\n<h3><strong>\u591a\u4e2a\u83b7\u6279\u9002\u5e94\u75c7\uff0c\u6570\u5341\u4e2a\u9002\u5e94\u75c7\u540c\u4e49\u8bcd<\/strong><\/h3>\n<p>\u5355\u4e00\u8d44\u4ea7\u7684\u4e34\u5e8a\u590d\u6742\u6027\u589e\u52a0\u4e86\u7b2c\u4e09\u5c42\u96be\u5ea6\u3002\u81ea 2021 \u5e74\u4ee5\u6765\uff0clisocabtagene maraleucel \u5df2\u83b7\u5f97 FDA \u6279\u51c6\u7528\u4e8e\u4e94\u79cd\u9002\u5e94\u75c7\uff1a<sup>1, 5<\/sup><\/p>\n<ol>\n<li>\u5927 B \u7ec6\u80de\u6dcb\u5df4\u7624\uff08\u9996\u6b21\u83b7\u6279\uff0c2021 \u5e74 2 \u6708\uff09<\/li>\n<li>\u6162\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7ec6\u80de\u6dcb\u5df4\u7624\uff082024 \u5e74 3 \u6708\uff09<sup>8<\/sup><\/li>\n<li>\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\uff082024 \u5e74 5 \u6708\uff09<sup>6<\/sup><\/li>\n<li>\u5957\u7ec6\u80de\u6dcb\u5df4\u7624\uff082024 \u5e74 5 \u6708\uff09<sup>8<\/sup><\/li>\n<li>\u8fb9\u7f18\u533a\u6dcb\u5df4\u7624\uff082025 \u5e74 12 \u6708\uff09<sup>5<\/sup><\/li>\n<\/ol>\n<p>\u8fd9\u4e9b\u9002\u5e94\u75c7\u4e2d\u7684\u6bcf\u4e00\u79cd\u5728\u533b\u5b66\u6587\u732e\u4e2d\u90fd\u6709\u5176\u81ea\u8eab\u7684\u672f\u8bed\u3002\u5f25\u6f2b\u6027\u5927 B \u7ec6\u80de\u6dcb\u5df4\u7624\u5728\u6587\u732e\u4e2d\u7684\u8868\u8ff0\u6709 DLBCL\u3001DLBCL NOS \u6216\u4fb5\u88ad\u6027\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u3002\u6ee4\u6ce1\u6027\u6dcb\u5df4\u7624\u8868\u8ff0\u4e3a FL\u3001FNHL \u6216\u5c0f\u6ee4\u6ce1\u4e2d\u5fc3\u7ec6\u80de\u6dcb\u5df4\u7624\u5747\u53ef\u3002\u8fb9\u7f18\u533a\u6dcb\u5df4\u7624\u5728\u4e0d\u540c\u4fe1\u606f\u6765\u6e90\u4e2d\u5206\u4e3a MZL\u3001MALT \u6dcb\u5df4\u7624\u548c\u9ecf\u819c\u76f8\u5173\u6dcb\u5df4\u7ec4\u7ec7\u6dcb\u5df4\u7624\u3002<\/p>\n<p>\u66f4\u590d\u6742\u7684\u662f\uff0c\u5e76\u975e\u6bcf\u4e2a\u4fe1\u606f\u6765\u6e90\u90fd\u6db5\u76d6\u6bcf\u4e00\u4e2a\u9002\u5e94\u75c7\u3002\u65e9\u671f\u7684\u671f\u520a\u4e3b\u8981\u5173\u6ce8\u6700\u521d\u7684 DLBCL \u9879\u76ee\u3002\u76d1\u7ba1\u7533\u62a5\u6587\u4ef6\u53cd\u6620\u7684\u662f\u9012\u4ea4\u7533\u8bf7\u65f6\u7684\u83b7\u6279\u4eba\u7fa4\u3002\u4f1a\u8bae\u6458\u8981\u63cf\u8ff0\u7684\u8bd5\u9a8c\u961f\u5217\u5f80\u5f80\u662f\u5bf9\u5e94\u6570\u5e74\u540e\u624d\u83b7\u6279\u7684\u9002\u5e94\u75c7\u3002\u53ea\u6709\u5c06\u6240\u6709\u8fd9\u4e9b\u788e\u7247\u4fe1\u606f\u8de8\u65f6\u95f4\u7ebf\u8fde\u63a5\u8d77\u6765\uff0c\u624d\u80fd\u8fd8\u539f\u5b8c\u6574\u7684\u4e34\u5e8a\u5168\u8c8c\u3002<\/p>\n<h3><strong>\u5927\u89c4\u6a21\u7cbe\u9009\u533b\u836f\u60c5\u62a5\u7684\u5448\u73b0\u65b9\u5f0f<\/strong><\/h3>\n<p>Cortellis Competitive Intelligence \u6301\u7eed\u8ffd\u8e2a\u8d85\u8fc7 101,000 \u79cd\u7ba1\u7ebf\u836f\u7269\u548c\u8d85\u8fc7 32,000 \u79cd\u5904\u4e8e\u65e9\u671f\u7814\u7a76\u9636\u6bb5\u7684\u836f\u7269\uff0c\u5176\u8986\u76d6\u8303\u56f4\u6a2a\u8de8 3,000 \u591a\u79cd\u75be\u75c5\u3001690 \u591a\u4e07\u9879\u4e13\u5229\u548c 316,000 \u591a\u4efd\u516c\u53f8\u6863\u6848\uff0c\u8d2f\u7a7f\u6574\u4e2a\u836f\u7269\u5f00\u53d1\u751f\u547d\u5468\u671f\u3002\u53ea\u6709\u5f53\u57fa\u7840\u6570\u636e\u88ab\u6b63\u786e\u5173\u8054\u65f6\uff0c\u5982\u6b64\u89c4\u6a21\u7684\u6570\u636e\u624d\u5177\u6709\u4ef7\u503c\u3002<sup>13<\/sup><\/p>\n<p>Cortellis \u4e2d\u7684\u6bcf\u4e00\u6761\u8bb0\u5f55\u90fd\u53cd\u6620\u4e86\u4e00\u5957\u56f4\u7ed5\u4e09\u5927\u57fa\u7840\u6784\u5efa\u7684\u6574\u7406\u6d41\u7a0b\u3002\u9886\u57df\u4e13\u5bb6\u5bf9\u4fe1\u606f\u6765\u6e90\u8fdb\u884c\u5ba1\u67e5\u548c\u9a8c\u8bc1\uff0c\u89e3\u51b3\u81ea\u52a8\u6c47\u603b\u65e0\u6cd5\u6355\u6349\u7684\u6a21\u7cca\u4e4b\u5904\u3002\u901a\u8fc7\u8d2f\u5f7b\u7edf\u4e00\u7684\u7f16\u8f91\u6807\u51c6\uff0c\u786e\u4fdd\u4f01\u4e1a\u81ea\u884c\u62ab\u9732\u7684\u7ba1\u7ebf\u6570\u636e\u4e0e\u540c\u884c\u8bc4\u5ba1\u7684\u671f\u520a\u6570\u636e\u5177\u6709\u540c\u7b49\u53ef\u9760\u6027\u3002\u5e76\u4e14\uff0c\u672c\u4f53\u7d22\u5f15\u5c06\u6bcf\u4e2a\u522b\u540d\u3001\u7814\u53d1\u4ee3\u53f7\u3001\u54c1\u724c\u540d\u79f0\u548c\u63cf\u8ff0\u6027\u672f\u8bed\u6620\u5c04\u5230\u5355\u4e00\u6743\u5a01\u5b9e\u4f53\u2014\u2014\u6db5\u76d6\u8d85\u8fc7 700 \u79cd\u540c\u884c\u8bc4\u5ba1\u671f\u520a\u3001\u8d85\u8fc7 100 \u573a\u79d1\u5b66\u4f1a\u8bae\u3001\u5168\u7403 7 \u5927\u4e3b\u8981\u4e13\u5229\u5c40\u4ee5\u53ca\u5305\u62ec FDA\u3001\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u3001\u65e5\u672c\u836f\u54c1\u548c\u533b\u7597\u5668\u68b0\u7ba1\u7406\u5c40\uff08PMDA\uff09\u548c\u6fb3\u5927\u5229\u4e9a\u836f\u54c1\u7ba1\u7406\u5c40\uff08TGA\uff09\u5728\u5185\u7684\u4e3b\u8981\u76d1\u7ba1\u673a\u6784\u3002<\/p>\n<p>\u81f3\u5173\u91cd\u8981\u7684\u662f\uff0c\u5386\u53f2\u8bb0\u5f55\u5f97\u4ee5\u4fdd\u5b58\u3002\u4e00\u4e2a\u5728 2016 \u5e74\u4f7f\u7528\u7684\u6807\u8bc6\u7b26\uff0c\u5230 2026 \u5e74\u4ecd\u7136\u80fd\u5173\u8054\u5230\u6700\u7ec8\u83b7\u6279\u7684\u4ea7\u54c1\u3002\u4e00\u5bb6\u7ecf\u8fc7\u4e24\u6b21\u6536\u8d2d\u800c\u88ab\u5e76\u5165\u7684\u516c\u53f8\uff0c\u5176\u5b8c\u6574\u7684\u7814\u53d1\u5386\u53f2\u4ecd\u7136\u5f97\u4ee5\u5ef6\u7eed\u3002\u641c\u7d22\u201cMALT \u6dcb\u5df4\u7624\u201d\u4e0e\u641c\u7d22\u201c\u8fb9\u7f18\u533a B \u7ec6\u80de\u6dcb\u5df4\u7624\u201d\u4f1a\u8fd4\u56de\u76f8\u540c\u7684\u7ed3\u679c\u3002<\/p>\n<p>Liso-cel \u7684\u6848\u4f8b\u5e76\u975e\u4e2a\u6848\u3002\u5728 Cortellis \u6570\u636e\u5e93\u8ffd\u8e2a\u7684\u8d85\u8fc7 101,000 \u4e2a\u9879\u76ee\u4e2d\uff0c\u8fd9\u79cd\u60c5\u51b5\u66f4\u63a5\u8fd1\u4e8e\u5e38\u6001\u3002<\/p>\n<p><strong><i>\u4e86\u89e3\u66f4\u591a\u5173\u4e8e\u00a0<\/i><\/strong><strong><i>Cortellis\u00a0Competitive\u00a0Intelligence\u00a0<\/i><\/strong><strong><i>\u5982\u4f55\u5e2e\u52a9\u5236\u836f\u548c\u751f\u7269\u6280\u672f\u56e2\u961f\u4ece\u88ab\u52a8\u8ffd\u8e2a\u8f6c\u5411\u4e3b\u52a8\u6218\u7565\u8fdc\u89c1\uff1a<\/i><\/strong><a href=\"https:\/\/clarivate.com.cn\/life-sciences-healthcare\/portfolio-strategy\/competitive-intelligence\/cortellis-competitive-intelligence-analytics\/\"><strong><i>Cortellis\u00a0\u7ade\u4e89\u60c5\u62a5\u6570\u636e\u5e93\u00a0|\u00a0\u79d1\u777f\u552f\u5b89<\/i><\/strong><\/a><\/p>\n<p><i>Cortellis\u00a0\u5185\u5bb9\u5206\u6790\u90e8\u7684\u00a0Suzanne\u00a0Bodiam\u00a0\u4e3a\u672c\u6587\u63d0\u4f9b\u4e86\u652f\u6301\u3002<\/i><\/p>\n<p>&nbsp;<\/p>\n<h3><strong>\u53c2\u8003\u6587\u732e<\/strong><\/h3>\n<ol>\n<li>Food and Drug Administration. (2026, March 11). <em>BREYANZI<\/em>. Retrieved from <a href=\"https:\/\/www.fda.gov\" target=\"_blank\" rel=\"noopener\">www.fda.gov<\/a>: <a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi\" target=\"_blank\" rel=\"noopener\">https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi<\/a><\/li>\n<li>Securities Exchange Commission. (2018, March 6). <em>CELGENE COMPLETES ACQUISITION OF JUNO THERAPEUTICS, INC.,<\/em>. Retrieved from <a href=\"https:\/\/www.sec.gov\" target=\"_blank\" rel=\"noopener\">www.sec.gov<\/a>: <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm<\/a><\/li>\n<li>American Pharmaceutical Review. (2018, March 6). <em>Celgene Completes Acquisition of Juno Therapeutics<\/em>. Retrieved from <a href=\"https:\/\/www.americanpharmaceuticalreview.com\/1315-News\/347745-Celgene-Completes-Acquisition-of-Juno-Therapeutics\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.americanpharmaceuticalreview.com\/1315-News\/347745-Celgene-Completes-Acquisition-of-Juno-Therapeutics\/<\/a><\/li>\n<li>Schubert, C. (2019, January 10). <em>Bristol-Myers Squibb\u2019s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert<\/em>. Retrieved from GeekWire: <a href=\"https:\/\/www.geekwire.com\/2019\/bristol-myers-squibbs-74b-acquisition-juno-parent-celgene-puts-seattle-biotech-world-alert\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.geekwire.com\/2019\/bristol-myers-squibbs-74b-acquisition-juno-parent-celgene-puts-seattle-biotech-world-alert\/<\/a><\/li>\n<li>Bristol Myers Squibb. (2025, December 4). <em>Bristol Myers Squibb\u2019s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)<\/em>. Retrieved from news.bms.com: <a href=\"https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibbs-Breyanzi-Approved-by-the-U-S\u2013FDA-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL\/default.aspx\" target=\"_blank\" rel=\"noopener\">https:\/\/news.bms.com\/news\/corporate-financial\/2025\/Bristol-Myers-Squibbs-Breyanzi-Approved-by-the-U-S-FDA-as-the-First-and-Only-CAR-T-Cell-Therapy-for-Adults-with-Relapsed-or-Refractory-Marginal-Zone-Lymphoma-MZL\/default.aspx<\/a><\/li>\n<li>National Institutes of Health. (2025, August 22). <em>FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma<\/em>. Retrieved from NIH National Library of Medicine: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12369282\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12369282\/<\/a><\/li>\n<li>Bristol Myers Squibb. (n.d.). <em>Breyanzi<\/em>. Retrieved from <a href=\"https:\/\/www.breyanzi.com\" target=\"_blank\" rel=\"noopener\">breyanzi.com<\/a>: <a href=\"https:\/\/www.breyanzi.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.breyanzi.com\/<\/a><\/li>\n<li>American Association for Cancer Research. (2024). <em>Lisocabtagene Maraleucel Approved for Aggressive Lymphoma<\/em>. Retrieved from <a href=\"https:\/\/www.aacr.org\" target=\"_blank\" rel=\"noopener\">aacr.org<\/a>: <a href=\"https:\/\/www.aacr.org\/patients-caregivers\/progress-against-cancer\/lisocabtagene-maraleucel-approved-for-aggressive-lymphoma\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.aacr.org\/patients-caregivers\/progress-against-cancer\/lisocabtagene-maraleucel-approved-for-aggressive-lymphoma\/<\/a><\/li>\n<li>Taylor, P. (2018, January 22). <em>Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017<\/em>. Retrieved from Fierce Biotech: <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017\" target=\"_blank\" rel=\"noopener\">https:\/\/www.fiercebiotech.com\/biotech\/celgene-confirms-9bn-juno-buyout-sees-3bn-sales-for-jcar017<\/a><\/li>\n<li>Inman, S. (2018, January 22). <em>Celgene Acquiring Juno Therapeutics for $9 Billion<\/em>. Retrieved from OncLive: <a href=\"https:\/\/www.onclive.com\/view\/celgene-acquires-juno-therapeutics-for-9-billion\" target=\"_blank\" rel=\"noopener\">https:\/\/www.onclive.com\/view\/celgene-acquires-juno-therapeutics-for-9-billion<\/a><\/li>\n<li>Securities Exchange Commission. (2018, January 22). <em>CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY<\/em>. Retrieved from <a href=\"https:\/\/www.sec.gov\" target=\"_blank\" rel=\"noopener\">www.sec.gov<\/a>: <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418002935\/tv483707_ex99-2.htm\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418002935\/tv483707_ex99-2.htm<\/a><\/li>\n<li><em>JUNO THERAPEUTICS, INC.,<\/em>. Retrieved from <a href=\"https:\/\/www.sec.gov\" target=\"_blank\" rel=\"noopener\">sec.gov<\/a>: <a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sec.gov\/Archives\/edgar\/data\/816284\/000114420418012947\/tv487762_99-2.htm<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>2018 \u5e74 3 \u6708\uff0cCelgene \u4ee5 90 \u4ebf\u7f8e\u5143\u5b8c\u6210\u5bf9 Juno Therapeutics \u7684\u6536\u8d2d\uff0c\u4ece\u800c\u83b7\u5f97\u5f53\u65f6\u540d\u4e3a JCAR017 \u7684\u5d4c\u5408\u6297\u539f\u53d7\u4f53 T \u7ec6\u80de\uff08CAR-T\uff09\u7597\u6cd5\u9879\u76ee\u7684\u5168\u90e8\u6743\u76ca\u3002\u4e00\u5e74\u540e\uff0c\u767e\u65f6\u7f8e\u65bd\u8d35\u5b9d\u4ee5 740 \u4ebf\u7f8e\u5143\u6536\u8d2d\u4e86 Celgene\uff0c\u8be5\u8d44\u4ea7\u4e5f\u968f\u4e4b\u6613\u4e3b\u3002\u622a\u81f3 2021 \u5e74\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e86\u8be5\u836f\u7269\uff0c\u5176\u4f7f\u7528\u7684\u540d\u79f0\u662f\u4e1a\u5185\u5927\u591a\u6570\u4eba\u5728\u5176\u5f00\u53d1\u8fc7\u7a0b\u4e2d\u4ece\u672a\u542c\u95fb\u8fc7\u7684\uff1alisocabtagene maraleucel\uff0c\u5546\u54c1\u540d\u4e3a Breyanzi\u30021, 2, 3, 4 \u5982\u4eca\uff0cBreyanzi \u662f\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u4e94\u79cd\u4e0d\u540c\u764c\u75c7\u7c7b\u578b\u7684 CAR-T \u7597\u6cd5\u3002\u8fd9\u4e5f\u6070\u597d\u8bf4\u660e\u4e86\u4e3a\u4ec0\u4e48\u5efa\u7acb\u4e00\u4e2a\u53ef\u9760\u7684\u836f\u7269\u7ade\u4e89\u60c5\u62a5\u6570\u636e\u5e93\u5982\u6b64\u56f0\u96be\u2014\u2014\u4ee5\u53ca\u4e3a\u4ec0\u4e48\u7ecf\u6574\u7406\u7684\u60c5\u62a5\u4e0e\u539f\u59cb\u6570\u636e\u6c47\u603b\u4e4b\u95f4\u7684\u5dee\u5f02\uff0c\u5bf9\u4e8e\u4f9d\u8d56\u4e8e\u6b64\u7684\u6bcf\u4e00\u9879\u51b3\u7b56\u800c\u8a00\u90fd\u81f3\u5173\u91cd\u8981\u30025 \u4e3a\u4ec0\u4e48\u836f\u7269\u547d\u540d\u4f1a\u4f7f\u836f\u7269\u6570\u636e\u5982\u6b64\u590d\u6742 \u4e00\u79cd\u836f\u7269\u4ece\u5b66\u672f\u5b9e\u9a8c\u5ba4\u7ecf\u7531\u521d\u521b\u516c\u53f8\u3001\u6536\u8d2d\u65b9\u76f4\u81f3\u5168\u7403\u5236\u836f\u516c\u53f8\uff0c\u5b83\u5728\u6bcf\u4e2a\u9636\u6bb5\u90fd\u4f1a\u7d2f\u79ef\u4e0d\u540c\u7684\u6807\u8bc6\u7b26\u3002\u6bcf\u4e00\u4e2a\u6807\u8bc6\u7b26\u5728\u5176\u51fa\u73b0\u7684\u80cc\u666f\u4e0b\u90fd\u662f\u6b63\u786e\u7684\u3002\u6bcf\u4e00\u4e2a\u90fd\u51fa\u73b0\u5728\u4e0d\u540c\u7c7b\u578b\u7684\u4fe1\u606f\u6765\u6e90\u4e2d\u3002\u8fd9\u4e9b\u6807\u8bc6\u7b26\u4e4b\u95f4\u5e76\u4e0d\u4f1a\u81ea\u52a8\u5efa\u7acb\u5173\u8054\u3002&#8230;<\/p>\n","protected":false},"author":13,"featured_media":436131,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[43,3],"tags":[69,60,56],"class_list":["post-436128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-life-sciences-healthcare","tag-market-access","tag-case-study","tag-pharmaceutical-regulations"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-21 01:45:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/436128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=436128"}],"version-history":[{"count":7,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/436128\/revisions"}],"predecessor-version":[{"id":436136,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/436128\/revisions\/436136"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/436131"}],"wp:attachment":[{"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=436128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=436128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.clarivate.com.cn\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=436128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}